Infectious scleritis – Case series in Indian population
Accept poster if oral is not possible ?
Yes
Purpose
To study the clinical features, diagnosis & treatment outcome in patients with infectious scleritis.
Methods
Retrospective study between 2012 & 2019
Results
34 eyes. Mean age -51.43 yrs (±18.30). Mean duration of symptoms-2.83 months (±4.41.) presenting as redness (100%), pain (85.3%) & decreased vision (41.2%). Risk factors included injury in 29%, surgery in 26%(vitrectomy 5, cataract surgery 3 and scleral buckle 1 eye). Pre treatment mean visual acuity-1.44 logmar(±1.09). Clinical presentation included 33 anterior and 1 posterior scleritis. Unifocal in 38%, multifocal in 35% & diffuse in 26%. Uveitis was seen in 41%, keratitis in 29%, subretinal abscess in 6% & exudative retinal detachment, endophthalmitis & panophthalmitis in 1 eye each. Bacteria was seen in 50%, fungus 41%, herpes virus 6% & mixed in 3%. Mean duration of symptoms was longer in fungal (2.45 months ± 2.88) than bacterial scleritis (1.17±0.89 months). All patients were treated with antimicrobials, scleral debridement & patch graft. Mean time of healing was longer in fungal (3.02±1.74 months) than bacterial (2.86±1.67 months). Follow up range - 5 weeks to 4.5 yrs. 28 eyes had complete resolution. 1 eye each required enucleation and evisceration. Causes of decreased vision were corneal scar, glaucoma, macular scar and phthisis bulbi. On univariate analysis, poor visual acuity at presentation resulted in a worse visual outcome (P=0.062). Average time of healing was longer in diffuse and multifocal scleritis (P=0.365).
Conclusion
Early diagnosis & treatment helps in complete resolution of infectious scleritis.
Conflict of interest
No
Author 1
Last name
AGARWAL
Initials of first name(s)
M
Department
Uveitis & Cornea Services , Sankara Nethralaya
City
Chennai
Country
India
Author 2
Last name
Biswas
Initials of first name(s)
J
Department
Uveitis Services
City
Chennai
Country
India
This website uses cookies to ensure you get the best experience on our website.
Learn more